Lv51
1326 积分 2023-12-25 加入
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
1小时前
待确认
BCMA CARs in multiple myeloma: room for more?
2小时前
待确认
Application of thrombopoietic agents in cancer therapy-induced thrombocytopenia: A comprehensive review
4天前
已完结
Selinexor for advanced hematologic malignancies
8天前
已完结
The nuclear export protein XPO1 — from biology to targeted therapy
8天前
已完结
Aiming for the cure in myeloma: Putting our best foot forward
14天前
已完结
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
14天前
已完结
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
14天前
已完结
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
15天前
已完结
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
16天前
已完结
皖公网安备34019202002308
